Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 22OTHER 16NIH 2NETWORK 2OTHER_GOV 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 2Adenocarcinoma 1

Interventions

Specimen Handling 46Magnetic Resonance Spectroscopy 37Cyclophosphamide 28Vincristine 20Radiation 19Dexamethasone 19Cisplatin 18Biopsy 18Radiotherapy 17Etoposide 17Carboplatin 16Cytarabine 13Leucovorin 12daratumumab 11Methotrexate 11durvalumab 10Standard of Care 10Radiotherapy, Intensity-Modulated 10Platinum 10Gemcitabine 10Doxorubicin 10Docetaxel 10Practice Guidelines as Topic 9Calcium Dobesilate 91,2-diaminocyclohexaneplatinum II citrate 9merphos 8dexamethasone acetate 8dexamethasone 21-phosphate 8auricularum 8X-Rays 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × darolutamide × 90 days × Clear all
NCT04484818 2026-05-05

Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study

Eastern Cooperative Oncology Group

Phase 3 Active not recruiting
27 enrolled
Genitourinary

Prostatic Neoplasms

NCT06592924 2026-04-14

TRIPLE-SWITCH

Canadian Cancer Trials Group

Phase 3 Recruiting
830 enrolled
Genitourinary

Adenocarcinoma, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡